KRAS G12C-mutated Metastatic Colorectal Cancer: Current Therapeutic Strategies and Future Directions
Journal of Gastrointestinal Cancer · 18.08.2026 · 57 (1)
DOI: 10.1007/s12029-026-01547-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Gastrointestinal Cancer, online erschienen am 18.08.2026. Verfasst von Tamotsu Sagawa und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan. stamotsu@jk9.so-net.ne.jp. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Antineoplastic Combined Chemotherapy Protocols, Oncogene Protein p21(ras). Die Arbeit nennt 21 Literaturangaben.
Abstract (Originalsprache)
KRAS G12C mutations define a small but clinically important molecular subset of metastatic colorectal cancer (mCRC), accounting for approximately 3% to 4% of cases and remaining associated with substantial unmet need after standard chemotherapy. Although direct KRAS G12C inhibitors have transformed treatment in other tumor types, their activity as monotherapy in mCRC has been modest, largely because colorectal cancer retains strong upstream EGFR and receptor tyrosine kinase dependency with adaptive MAPK pathway reactivation. These observations provide the biologic rationale for combined KRAS G12C and EGFR inhibition. Clinical results are line- and regimen-dependent: sotorasib plus panitumumab improved progression-free survival compared with standard later-line therapy in the randomized phase 3 CodeBreaK 300 trial, whereas adagrasib plus cetuximab demonstrated clinically meaningful activity in KRYSTAL-1 but did not improve progression-free or overall survival versus chemotherapy in the second-line phase 3 KRYSTAL-10 trial despite a higher objective response rate. Available evidence should therefore be interpreted with appropriate caution. Moreover, acquired resistance remains common and frequently polyclonal, involving secondary KRAS alterations, receptor tyrosine kinase bypass, and downstream pathway reactivation. In this review, we summarize the biologic rationale, current clinical evidence, practical guideline-based positioning, toxicity management considerations, resistance mechanisms, and emerging therapeutic strategies for KRAS G12C-mutated mCRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan. stamotsu@jk9.so-net.ne.jp.
- Department of Gastroenterology, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan.
Zitieren
APA
Sagawa, T., Nagashima, H., & Fujikawa, K. (2026). KRAS G12C-mutated Metastatic Colorectal Cancer: Current Therapeutic Strategies and Future Directions. Journal of Gastrointestinal Cancer, 57(1). https://doi.org/10.1007/s12029-026-01547-2
Vancouver
Sagawa T, Nagashima H, Fujikawa K. KRAS G12C-mutated Metastatic Colorectal Cancer: Current Therapeutic Strategies and Future Directions. Journal of Gastrointestinal Cancer. 2026;57(1). doi:10.1007/s12029-026-01547-2
BibTeX
@article{Sagawa2026,
author = {Sagawa, Tamotsu and Nagashima, Hiroyuki and Fujikawa, Koshi},
title = {KRAS G12C-mutated Metastatic Colorectal Cancer: Current Therapeutic Strategies and Future Directions},
journal = {Journal of Gastrointestinal Cancer},
year = {2026},
volume = {57},
number = {1},
doi = {10.1007/s12029-026-01547-2}
}
EUVIMED